Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more
Shinpoong Pharmaceutical Co Ltd (019175) - Total Assets
Latest total assets as of September 2025: ₩341.59 Billion KRW
Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) holds total assets worth ₩341.59 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shinpoong Pharmaceutical Co Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shinpoong Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shinpoong Pharmaceutical Co Ltd's total assets of ₩341.59 Billion consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 12.3% |
| Accounts Receivable | ₩70.16 Billion | 20.5% |
| Inventory | ₩55.38 Billion | 16.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.01 Billion | 1.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shinpoong Pharmaceutical Co Ltd's current assets represent 55.3% of total assets in 2024, an increase from 51.6% in 2014.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2024, up from 1.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 20.5% of total assets.
Shinpoong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shinpoong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Shinpoong Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shinpoong Pharmaceutical Co Ltd generates 0.65x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shinpoong Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Shinpoong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.74 | 2.92 | 3.99 |
| Quick Ratio | 1.90 | 2.10 | 3.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩123.55 Billion | ₩ 127.35 Billion | ₩ 249.47 Billion |
Shinpoong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shinpoong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.11 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.3% |
| Total Assets | ₩342.09 Billion |
| Market Capitalization | $386.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shinpoong Pharmaceutical Co Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shinpoong Pharmaceutical Co Ltd's assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shinpoong Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual total assets of Shinpoong Pharmaceutical Co Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩342.09 Billion | -2.28% |
| 2023-12-31 | ₩350.08 Billion | -3.17% |
| 2022-12-31 | ₩361.54 Billion | -7.91% |
| 2021-12-31 | ₩392.58 Billion | -19.41% |
| 2020-12-31 | ₩487.15 Billion | +28.16% |
| 2019-12-31 | ₩380.11 Billion | -0.22% |
| 2018-12-31 | ₩380.95 Billion | -1.21% |
| 2017-12-31 | ₩385.61 Billion | -7.41% |
| 2016-12-31 | ₩416.49 Billion | +1.40% |
| 2015-12-31 | ₩410.73 Billion | +0.35% |
| 2014-12-31 | ₩409.30 Billion | -- |